The effect of mirabegron on patient-related outcomes in patients with overactive bladder: the results of post hoc correlation and responder analyses using pooled data from three randomized Phase III trials

PURPOSE: To understand how improvements in the symptoms of overactive bladder (OAB) seen with the β(3)-adrenoceptor agonist mirabegron 50 mg, correlate with patient experience as measured by validated and standard patient-reported outcomes (PROs), and to identify whether there is overall directional...

Descripción completa

Detalles Bibliográficos
Autores principales: Castro-Diaz, D., Chapple, C. R., Hakimi, Z., Blauwet, M. B., Delgado-Herrera, L., Lau, W., Mujais, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4483243/
https://www.ncbi.nlm.nih.gov/pubmed/25688038
http://dx.doi.org/10.1007/s11136-014-0904-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4483243/
https://www.ncbi.nlm.nih.gov/pubmed/25688038
http://dx.doi.org/10.1007/s11136-014-0904-4

Ejemplares similares